NextCell Pharma | NextCell Pharma and The Stem Cell Revolution

NextCell's Product Portfolio

NextCell develops novel stromal cell therapies, with a primary focus on type 1 diabetes. The lead candidate ProTrans, is based on NextCell patented selection algorithm. NextCell also runs Cellaviva, Scandinavia's largest private stem cell bank.

About NextCell

NextCell is a Swedish biopharmaceutical company running two business areas with the same core – stem and stromal cells from umbilical cord. NextCell is focusing on research and development of novel stromal cell therapies and also runs a tissue establishment and primary biobank, classified as a healthcare provider.

Investors

NextCell is listed on the Nasdaq First North Growth Market. Here you will find information about the share, the latest reports and other financial data.

News

2025-10-30

NextCell Pharma publishes its Interim Report 4 2024/2025

Regulatory

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 4 for the period June 1, 2025 – August 31, 2025. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year. . Please note that the Company's financial year is now 1 January - 31 December. This means that for the year 2025, this Q4 report will be followed by a Year-end report at the end of February 2026, covering the period September-December 2025.

Read more Read more

2025-09-18

NextCell Pharma AB announces CFO transition

Regulatory

NextCell Pharma AB (“NextCell” or the “Company”) today announces that the Company’s CFO, Patrik Fagerholm, has decided to step down to take on a new assignment. Patrik will remain in his role throughout the notice period to ensure a smooth transition. The recruitment process to identify a successor for the CFO position has been initiated.

Read more Read more

2025-07-24

NextCell Pharma publishes its Interim Report 3 2024/2025

Regulatory

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period March 1, 2025 – May 31, 2025. This English version of the Interim Report is a translation of the Swedish version. The Swedish version is the official version. The report is available on the company's website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Read more Read more

2025-07-14

NextCell Highlighted in FUJIFILM’s Strategic Vision, According to GEN

Regulatory

NextCell Pharma AB (“NextCell” or “the Company”) is pleased to announce that its strategic collaboration with FUJIFILM Biosciences has been highlighted in an article published on 8 July by Genetic Engineering & Biotechnology News (GEN). The article covers FUJIFILM’s recent rebranding and long-term ambition to act as a full-spectrum partner to drug and vaccine developers throughout the entire development cycle.

NextCell – Part of the Stem Cell Revolution

NextCell's Product Portfolio

About NextCell

Investors

News

NextCell Pharma publishes its Interim Report 4 2024/2025

NextCell Pharma AB announces CFO transition

NextCell Pharma publishes its Interim Report 3 2024/2025

NextCell Highlighted in FUJIFILM’s Strategic Vision, According to GEN

Subscribe to press releases